Analysguiden announces new research report with the target price for ExpreS2ion at 24 SEK per share

Report this content

Hørsholm, Denmark, January 27, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.

The major contributors of value in the sum-of-the-parts valuation are the PREVENT-nCoV COVID-19 vaccine program, now designated ABNCoV2 under exclusive license to Bavarian Nordic, and ExpreS2ion’s planned exercise of the option to inlicense the AV001/ES2B-C001 breast cancer vaccine candicate from its joint venture partner AdaptVac ApS.

The full English version of the company-sponsored equity research report is attached to this press release, while the Swedish version is available on Analysguiden’s website:

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732


For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit and